Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Elderly Subjects
NCT00500357
Last updated date
ABOUT THIS STUDY
This is a follow-up study to the core study NCT00269672 (6115A1-500). This study will further
evaluate the safety, tolerability, and immunogenicity of 13-valent pneumococcal conjugate
vaccine (13vPnC) when administered to subjects who have already received one dose of 13vPnC,
and one dose of 23-valent pneumococcal polysaccharide vaccine (23vPS) one year later. This
study will determine if a subsequent dose of 13vPnC one year later results in similar or
greater immune response (body's ability to protect against disease) than that measured after
the initial dose of 13vPnC.
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
By phone
Pfizer Clinical Trials Contact Center
1-800-718-1021
Eligibility Criteria
condition
Pneumococcal Conjugate Vaccine Vaccines
Sex
Females and Males
Age
65 + years
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
Pneumococcal Conjugate Vaccine VaccinesStudy Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in Brazil
NCT00676091
- Curitiba,
- Florianopolis,
- Sau Paulo,
- Sau Paulo,
ALL GENDERS
0+
years
MULTIPLE SITES
Pneumococcal Conjugate Vaccine VaccinesStudy Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants
NCT00475033
- Calgary, Alberta
- Edmonton, Alberta
- Coquitlam, British Columbia
- Surrey, British Columbia
- Vancouver, British Columbia
- Winnipeg, Manitoba
- Winnipeg, Manitoba
- Halifax, Nova Scotia
- Montreal, Quebec
- Montreal, Quebec
- Quebec City, Quebec
ALL GENDERS
42 Days+
years
MULTIPLE SITES
Pneumococcal Conjugate Vaccine VaccinesStudy Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Elderly Subjects
NCT00500357
- Amanzimtoti,
- Bishop Lavis,
- Bloemfontein,
- Brits,
- Cape Town,
- Cape Town,
- Lenasia,
- Paarl,
- Parow,
- Parys,
- Pretoria,
- Pretoria,
- Pretoria,
- Pretoria,
- Scottburgh South,
- Vanderbijlpark,
ALL GENDERS
65 Years+
years
MULTIPLE SITES
Pneumococcal Conjugate Vaccine VaccinesStudy Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Japanese Infants
NCT00574795
- Nagoya-shi, Aichi
- Toyohashi-shi, Aichi
- Chiba-shi, Chiba
- Matsuyama-shi, Ehime
- Fukuoka-shi, Fukuoka
- Fukuoka-shi, Fukuoka
- Fukuoka-shi, Fukuoka
- Fukuoka-shi, Fukuoka
- Maebaru-shi, Fukuoka
- Asahikawa-shi, Hokkaido
- Sapporo-shi, Hokkaido
- Sapporo-shi, Hokkaido
- Sapporo-shi, Hokkaido
- Yokohama-shi, Kanagawa
- Yokosuka-shi, Kanagawa
- Nangoku-shi, Kochi
- Ise-shi, Mie
- Tsu-shi, Mie
- Yokkaichi-shi, Mie
- Kurashiki-shi, Okayama
- Meguro-ku, Tokyo
- Setagaya-ku, Tokyo
- Setagaya-ku, Tokyo
- Setagaya-ku, Tokyo
ALL GENDERS
2 Months+
years
MULTIPLE SITES
Advanced Information
Descriptive Information | ||||
---|---|---|---|---|
Brief Title ICMJE | Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Elderly Subjects | |||
Official Title ICMJE | A Phase 3, Open-Label, Single-Arm Trial Evaluating the Safety, Tolerability, and Immunogenicity of a Subsequent Dose of 13-valent Pneumococcal Conjugate Vaccine Administered to One Group of Individuals Who Participated in Study 6115A1-500 | |||
Brief Summary | This is a follow-up study to the core study NCT00269672 (6115A1-500). This study will further evaluate the safety, tolerability, and immunogenicity of 13-valent pneumococcal conjugate vaccine (13vPnC) when administered to subjects who have already received one dose of 13vPnC, and one dose of 23-valent pneumococcal polysaccharide vaccine (23vPS) one year later. This study will determine if a subsequent dose of 13vPnC one year later results in similar or greater immune response (body's ability to protect against disease) than that measured after the initial dose of 13vPnC. | |||
Detailed Description | Not Provided | |||
Study Type ICMJE | Interventional | |||
Study Phase ICMJE | Phase 3 | |||
Study Design ICMJE | Allocation: Non-Randomized Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Prevention | |||
Condition ICMJE | Vaccines, Pneumococcal Conjugate Vaccine | |||
Intervention ICMJE | Biological: 13-valent Pneumococcal Conjugate Vaccine
1 dose 13vPnC | |||
Study Arms ICMJE | Not Provided | |||
Publications * | Juergens C, de Villiers PJ, Moodley K, Jayawardene D, Jansen KU, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B. Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine formulations with and without aluminum phosphate and comparison of the formulation of choice with 23-valent pneumococcal polysaccharide vaccine in elderly adults: a randomized open-label trial. Hum Vaccin Immunother. 2014;10(5):1343-53. doi: 10.4161/hv.27998. Epub 2014 Feb 27. | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
Recruitment Information | ||||
Recruitment Status ICMJE | Completed | |||
Actual Enrollment ICMJE | 105 | |||
Original Enrollment ICMJE | 150 | |||
Actual Study Completion Date ICMJE | January 2010 | |||
Actual Primary Completion Date | January 2010 (Final data collection date for primary outcome measure) | |||
Eligibility Criteria ICMJE |
| |||
Sex/Gender ICMJE |
| |||
Ages ICMJE | 65 Years and older (Older Adult) | |||
Accepts Healthy Volunteers ICMJE | Yes | |||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries ICMJE | South Africa | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number ICMJE | NCT00500357 | |||
Other Study ID Numbers ICMJE | 6115A1-3009 | |||
Has Data Monitoring Committee | No | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement ICMJE | Not Provided | |||
Responsible Party | Wyeth (Registry Contact: Clinical Trial Registry Specialist), Wyeth | |||
Study Sponsor ICMJE | Wyeth is now a wholly owned subsidiary of Pfizer | |||
Collaborators ICMJE | Not Provided | |||
Investigators ICMJE |
| |||
PRS Account | Wyeth is now a wholly owned subsidiary of Pfizer | |||
Verification Date | April 2011 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |